
==== Front
J Hematol Oncol
J Hematol Oncol
Journal of Hematology & Oncology
1756-8722
BioMed Central London

39272169
1587
10.1186/s13045-024-01587-w
Correspondence
Regimens combining radiation and immunotherapy for cancer: latest updates from 2024 ASCO Annual Meeting
Liu Di 1
Wu Leilei 1
Xu Xiaoling 1
Yang Shuangyan 1
Liu Ming 1
Hu Min 1
Ren Shengxiang harry_ren@126.com

2
Xu Yaping xuyaping1207@163.com

1
1 grid.24516.34 0000000123704535 Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, PR China
2 grid.24516.34 0000000123704535 Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, PR China
13 9 2024
13 9 2024
2024
17 845 7 2024
1 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Combination of immunotherapy with radiotherapy is under active investigation. The PACIFIC trial firmly established the treatment paradigm of consolidation immunotherapy following definitive chemoradiotherapy, inspiring a series of similar or exploratory combination regimens. This summary highlighted six reports updated in the 2024 ASCO Annual Meeting.

http://dx.doi.org/10.13039/501100003399 Science and Technology Commission of Shanghai Municipality 23Y11908700 Clinical Research Key Project of Shanghai Pulmonary HospitalFKLY20006 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcConsolidation immunotherapy following concurrent chemoradiotherapy

Consolidation immunotherapy following definitive concurrent chemoradiotherapy (cCRT) has been established as a standard treatment in unresectable locally advanced non-small cell lung cancer (LA-NSCLC) based on the PACIFIC trial [1]. This strategy was further validated in a real-world study with superior survival outcomes at ASCO 2024 [2]. Moreover, research has been conducted to investigate the efficacy of consolidation immunotherapy in limited-stage small-cell lung cancer (LS-SCLC). The phase III ADRIATIC study evaluated durvalumab as a consolidation treatment for LS-SCLC patients who had not experienced disease progression after cCRT (Table 1). Results from the study showed that durvalumab consolidation significantly prolonged overall survival [median OS (mOS): 55.9 vs. 33.4 months; HR 0.73; p = 0.0104] and progression-free survival [median PFS (mPFS): 16.6 vs. 9.2 months; HR 0.76; p = 0.0161] compared to placebo (Table 2). The incidence rates of grade 3/4 adverse events (AEs) were similar at 24%, with less than 3% experiencing grade 3/4 pneumonitis across both groups [3]. The ADRIATIC study would be a game-changer, and durvalumab would be a new standard of care for LS-SCLC after concurrent chemoradiotherapy.

Table 1 Combination studies with radiotherapy and immunotherapy in solid tumors

Cancer type	Stage	Study	Phase	Radiotherapy		Chemotherapy	Reference	
Scheme	Schedule	Scheme	Schedule	
SCLC*	Limited-stage	ADRIATIC	III	CFRT*	60-66 Gy/30fx*, qd* or 45 Gy/30fx, bid*		Concurrent	Etoposide + Platinum Q3W*, 3-4 Cycles	[3]	
ALK + NSCLC	Unresectable locally-advanced	-	R*	CFRT	-		Concurrent	Platinum-based#	[4]	
NPC*	Locoregionally advanced	BEACON	III	CFRT	PTVnx† 70 Gy/33fx, qd

PTVnd† 70 Gy/33fx, qd

PTV1† 60 Gy/33fx, qd

PTV2† 54 Gy/33fx, qd

		Induction-Concurrent	Induction: Gemcitabine + Cisplatin Q3W, 3 Cycles

Concurrent: Cisplatin Q3W, 3 Cycles

	[7]	
NSCLC	Locally advanced	GASTO-1091	II	Hypo-RT*	Hypo-RT (40 Gy/10fx or 30 Gy/6fx) + Hypo-RT-boost (24-30 Gy/6fx), qd		Neoadjuvant-

Concurrent

	Neoadjuvant: Docetaxel + Cisplatin Q3W, 2 Cycles

Concurrent: Docetaxel + Cisplatin QW*

	[8]	
STS*	III	SU2C-SARC032	II	CFRT	50 Gy/25fx, qd		-	-	[9]	
SCLC	Extensive-stage	-	III	-	≥ 30 Gy/10fx, qd or 50 Gy/25fx, qd		Induction	Etoposide + Platinum Q3W, 4-6 Cycles	[11]	
*Abbreviation: SCLC = Small-cell Lung Cancer; CFRT = Conventional Fractionated Radiotherapy; fx = fractions; qd = once a day; bid = Two times a day; Q3W = once every 3 weeks; R = Retrospective; NPC = Nasopharyngeal Carcinoma; Hypo-RT = Hypofractionated Radiotherapy; QW = once a week; STS = Soft Tissue Sarcoma

† PTVnx = planning target volumes for primary disease; PTVnd = planning target volumes involved lymph node; PTV1 = planning target volumes (high-risk); PTV2 = planning target volumes (low-risk)

# At least 2 doses of concurrent platinum-based chemotherapy and definitive radiation given between 2015–2022

Table 2 Outcomes of clinical trials with radiotherapy and immunotherapy in solid tumors

Treatment Patterns#	Patients (N*)	CRR (%)	ORR* (%)	median OS (m*)	median PFS (m)	Grade 3/4 AEs* (%)	Reference	
cCRT→CoIO vs. cCRT	264 vs. 266	-	-	55.9 vs. 33.4	16.6 vs. 9.2	24.4 vs. 24.2	[3]	
cCRT→CoTKI vs. cCRT→CoIO vs. cCRT	15 vs. 30 vs. 22	-	-	NR vs. NR vs. 70.6	NR vs. 11.3 vs. 7.4	27 vs. 7 vs. 6	[4]	
NeIO + CT→cCRT→AdIO vs. CT→cCRT	223 vs. 227	30.5 vs. 16.7	93.3 vs. 90.7	-	-	2.3 vs. 1.3	[7]	
NeIO + CT→hcCRT→AdIO vs. NeIO + CT→hcCRT	86 vs. 86	-	98.8 vs. 97.7	-	NR vs. 12.2	10.5 vs. 4.6	[8]	
NeIO + RT→Surgery→AdIO vs. RT→Surgery	71 vs. 72	-	-	-	HR 0.57†	52 vs. 26	[9]	
IO + CT→IO + RT→IOMaint	67	-	71.6	21.4	10.1	58.2	[11]	
# The treatment patterns observed in the studies are described by the following abbreviations:

IO = Immunotherapy; CoIO = Consolidation Immunotherapy; CoTKI = Consolidation TKI; NeIO = Neoadjuvant Immunotherapy; CT = Chemotherapy; AdIO = Adjuvant Immunotherapy; hcCRT = hypofractionated radiotherapy and concurrent chemotherapy; IOMaint = Immunotherapy maintenance. The arrow symbolized subsequent actions

* Abbreviation: N = Number; ORR = Objective Response Rate; m = months; AEs = adverse events

† The patients in this clinical trial underwent surgery, and therefore disease-free survival (DFS) was used as the evaluation factor. The hazard ratio (HR) of DFS for the two treatment arms was 0.57

While consolidation immunotherapy is the standard treatment for LA-NSCLC patients, its application in patients with a driver gene mutation is still largely unknown. A global retrospective study revealed consolidation with ALK tyrosine kinase inhibitors (ALK-TKI) significantly improved PFS in ALK-positive unresectable LA-NSCLC compared to durvalumab or observation after cCRT ([not reached [NR]] vs. 11.3 months vs. 7.4 months, p < 0.0001) (Table 2) [4]. Meanwhile, the LAURA study in this year’s ASCO meeting demonstrated that consolidation therapy with osimertinib following cCRT in EGFR-mutant locally advanced patients achieved a significantly prolonged median PFS of 39.1 months [5]. In contrast, in the PACIFIC trial, the median PFS of patients with EGFR mutations was 11.2 months. The ongoing BO42777 trial aims to evaluate the safety and efficacy of multiple targeted therapies compared to durvalumab for patients with unresectable stage III NSCLC [6]. The anticipated results will provide valuable insights into the efficacy of consolidation targeted therapies.

Neoadjuvant immunotherapy plus chemotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy

Researchers have been exploring immunotherapy as a component of a neoadjuvant strategy to improve survival outcomes in locally advanced tumors. Dr. Mai et al. reported the interim findings from the phase III BEACON study, which compared the efficacy of induction tislelizumab versus placebo combined with chemotherapy (gemcitabine-cisplatin), followed by cCRT and adjuvant tislelizumab or placebo in patients with locoregionally advanced nasopharyngeal carcinoma. The tislelizumab arm demonstrated a significant increase in the complete response rate (CRR) compared to the placebo arm (30.5% vs. 16.7%; p = 0.0006), meeting the primary endpoint (Table 2) [7]. It is expected that the significant tumor shrinkage effect would be converted into survival benefits.

The GASTO-1091 study enrolled unresectable LA-NSCLC patients who received neoadjuvant docetaxel, cisplatin, and nivolumab followed by hypofractionated cCRT (hypo-cCRT). The hypo-cCRT was administered with a dose of 40 Gy in 10 fractions (fx) or 30 Gy in 6fx, followed by a hypo-cCRT boost of 24-30 Gy in 6fx, resulting in a total dose of 60-64 Gy. Patients without progression or grade ≥ 2 pneumonitis after hypo-cCRT were subsequently randomized to receive nivolumab or undergo observation. The study’s primary endpoint was met, with the nivolumab group demonstrating significantly extended PFS compared to the observation group (NR vs. 12.2 months, p = 0.002) [8]. Notably, the control group in this study had a PFS of 12.2 months, which is substantially longer than the 5.6 months observed in the PACIFIC study’s control group. Additionally, both groups exhibited high overall response rates (ORR) with a minor difference (98.8% vs. 97.7%). These findings support further investigation of this innovative modality.

Neoadjuvant immunotherapy plus radiotherapy followed by surgery and adjuvant immunotherapy

A phase II study (SU2C-SARC032) demonstrated a significant enhancement in disease-free survival (DFS) when utilizing neoadjuvant pembrolizumab and radiotherapy (50 Gy/25fx), followed by surgery and adjuvant pembrolizumab (EXP), compared to standard radiotherapy and surgery (SOC) in undifferentiated pleomorphic sarcoma (UPS) and liposarcoma (LPS) (HR 0.57, 90%CI: 0.35-0.91; p = 0.023) (Table 2). The estimated 2-year DFS rate was higher in the EXP arm (70% vs. 53%) [9]. The superior DFS found in this study would potentially revolutionize the treatment paradigm for these specific cancer types in the future.

However, in terms of the AEs, the incidence of grade ≥ 3 was significantly higher in the EXP arm compared to the SOC arm in this study (52% vs. 26%, p = 0.002) (Table 2). Meanwhile, the PACIFIC-2 study evaluated the efficacy and safety of durvalumab in combination with cCRT, followed by consolidation durvalumab, as compared to placebo in patients with LA-NSCLC. The study did not demonstrate a statistically significant improvement in PFS (mPFS: 13.8 vs. 9.4 months, HR 0.85; 95% CI: 0.65-1.12; p = 0.247) or OS (mOS: 36.4 vs. 29.5 months, HR 1.03; 95% CI: 0.78-1.39; p = 0.823). Moreover, a notably higher percentage of patients experienced adverse events leading to the discontinuation of durvalumab compared to those receiving placebo (25.6% vs. 12.0%) [10], underscoring the importance of vigilant monitoring for potential adverse effects when concurrent combining immunotherapy with radiotherapy.

Sequential radiotherapy after first-line immunotherapy plus chemotherapy for advanced cancer

Local radiotherapy has shown promise in managing metastatic malignancies. Chen et al. reported on the efficacy and safety of sequential thoracic radiotherapy following immunotherapy plus EP/EC (etoposide and cisplatin or carboplatin) as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). Among patients who responded to treatment, radiotherapy was administrated at a dose of ≥ 30 Gy/10fx or 50 Gy/25fx. The median OS and PFS were 21.4 months (95%CI: 17.2-NR) and 10.1 months (95%CI: 6.9-15.5), respectively, after a median follow-up of 17.7 months. The one-year and two-year OS rates were found to be 74.1% and 39.7%, respectively, while grade ≥ 3 treatment-related AEs occurred in 58.2% of patients (Tables 1 and 2) [11]. Furthermore, a randomized phase III study on thoracic radiotherapy for ES-SCLC is ongoing, and its results are eagerly anticipated [12].

In conclusion, these results highlighted the importance of combining radiotherapy and immunotherapy in solid tumors. Consolidation immunotherapy following cCRT has demonstrated survival benefits in both LA-NSCLC and LS-SCLC. Meanwhile, neoadjuvant immunotherapy combined with chemotherapy/radiotherapy has shown significant tumor shrinkage effects and might convert to survival outcomes. Additionally, incorporating radiotherapy into first-line treatment for advanced tumors has yielded promising results. However, concurrent immunotherapy and radiotherapy are currently being tested for extremity sarcoma and might not be recommended off-trial for chest tumors due to the negative results observed in the PACIFIC-2 trial. Further study is needed to elucidate the potential underlying mechanism for proper cooperation of radiotherapy and immunotherapy in the future.

Acknowledgements

This is not applicable for this summary.

Author contributions

Yaping Xu and Shengxiang Ren designed the study. Yaping Xu, Di Liu, and Leilei Wu drafted the manuscript. Di Liu and Leilei Wu prepared the tables. Di Liu, Leilei Wu, Xiaoling Xu, Shuangyan Yang, Ming Liu, and Min Hu participated in the drafting process. Yaping Xu and Shengxiang Ren revised the manuscript.

Funding

The study is supported by the Science and Technology Commission of Shanghai Municipality (No. 23Y11908700) and the Clinical Research Key Project of Shanghai Pulmonary Hospital (FKLY20006).

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

This is not applicable for this summary.

Consent for publication

This is not applicable for this summary.

Competing interests

The authors declare no competing interests.

Abbreviations

cCRT Concurrent chemoradiotherapy

LA-NSCLC Locally advanced non-small cell lung cancer

LS-SCLC Limited-stage small-cell lung cancer

OS Overall survival

PFS Progression-free survival

AEs Adverse events

TKI Tyrosine kinase inhibitors

NR Not reached

CRR Complete response rate

hypo-cCRT Hypofractionated concurrent radiotherapy and chemotherapy

fx Fractions

ORR Overall response rates

DFS Disease-free survival

EXP Neoadjuvant pembrolizumab and radiotherapy followed by surgery and adjuvant pembrolizumab

SOC Standard radiation therapy and surgery

UPS Undifferentiated pleomorphic sarcoma

LPS Liposarcoma

ES-SCLC Extensive-stage small-cell lung cancer

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Di Liu and Leilei Wu contributed equally to this work.
==== Refs
References

1. Antonia SJ Villegas A Daniel D Vicente D Murakami S Hui R Yokoi T Chiappori A Lee KH de Wit M Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer New Engl J Med 2017 377 20 1919 29 10.1056/NEJMoa1709937 28885881
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. New Engl J Med. 2017;377(20):1919–29.28885881 10.1056/NEJMoa1709937
2. Mirsky MM Lee HJ Margevicius SP Carsel A Myers K Zablonski K Zhong J Fu P Wang Q Dowlati A Bruno DS Hsu ML Treatment outcomes in locally advanced, unresectable NSCLC treated with concurrent chemoradiation and PD-L1 consolidation: real-world data from a NCI comprehensive cancer center with a racially diverse, high poverty catchment area J Clin Oncol 2024 42 16suppl 8067 8067 10.1200/JCO.2024.42.16_suppl.8067
Mirsky MM, Lee HJ, Margevicius SP, Carsel A, Myers K, Zablonski K, Zhong J, Fu P, Wang Q, Dowlati A, Bruno DS, Hsu ML. Treatment outcomes in locally advanced, unresectable NSCLC treated with concurrent chemoradiation and PD-L1 consolidation: real-world data from a NCI comprehensive cancer center with a racially diverse, high poverty catchment area. J Clin Oncol. 2024;42(16suppl):8067–8067.10.1200/JCO.2024.42.16_suppl.8067
3. Spigel DR Cheng Y Cho BC Laktionov KK Fang J Chen Y Zenke Y Lee KH Wang Q Navarro A ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC) J Clin Oncol 2024 42 17suppl LBA5 5 10.1200/JCO.2024.42.17_suppl.LBA5
Spigel DR, Cheng Y, Cho BC, Laktionov KK, Fang J, Chen Y, Zenke Y, Lee KH, Wang Q, Navarro A. ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). J Clin Oncol. 2024;42(17suppl):LBA5–5.10.1200/JCO.2024.42.17_suppl.LBA5
4. Jayakrishnan R Nassar A Shepherd FA Lin JJ Lin SH Shakya P Dilling TJ Bar J Grohe C Gupta S Fitzgerald BG Adib E Sankar K Neal JW Yu HA Whitaker R Velazquez Manana AI Naqash AR Goldberg SB Kim SY Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK + non-small cell lung cancer (NSCLC) J Clin Oncol 2024 42 16suppl 8013 8013 10.1200/JCO.2024.42.16_suppl.8013
Jayakrishnan R, Nassar A, Shepherd FA, Lin JJ, Lin SH, Shakya P, Dilling TJ, Bar J, Grohe C, Gupta S, Fitzgerald BG, Adib E, Sankar K, Neal JW, Yu HA, Whitaker R, Velazquez Manana AI, Naqash AR, Goldberg SB, Kim SY. Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK + non-small cell lung cancer (NSCLC). J Clin Oncol. 2024;42(16suppl):8013–8013.10.1200/JCO.2024.42.16_suppl.8013
5. Ramalingam SS Kato T Dong X Ahn MJ Quang LV Soparattanapaisarn N Inoue T Wang CL Huang M Yang JCH Cobo M Özgüroğlu M Casarini I Khiem DV Sriuranpong V Cronemberger E Huang X Gronde Tvd, Ghiorghiu DC Lu S Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: primary results of the phase 3 LAURA study J Clin Oncol 2024 42 17suppl LBA4 4 10.1200/JCO.2024.42.17_suppl.LBA4
Ramalingam SS, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JCH, Cobo M, Özgüroğlu M, Casarini I, Khiem DV, Sriuranpong V, Cronemberger E, Huang X, Gronde Tvd, Ghiorghiu DC, Lu S. Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: primary results of the phase 3 LAURA study. J Clin Oncol. 2024;42(17suppl):LBA4–4.10.1200/JCO.2024.42.17_suppl.LBA4
6. Paz-Ares, Gay CM Zhou C Kato T Corrales L Redhead K Rahman A Bradley D Theogaraj E Hutchinson KE Shagan SM Solomon BJ A phase I-III platform study evaluating the safety and efficacy of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non–small-cell lung cancer (NSCLC) J Clin Oncol 2024 42 17suppl TPS8605 8605
Paz-Ares, Gay CM, Zhou C, Kato T, Corrales L, Redhead K, Rahman A, Bradley D, Theogaraj E, Hutchinson KE, Shagan SM, Solomon BJ. A phase I-III platform study evaluating the safety and efficacy of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non–small-cell lung cancer (NSCLC). J Clin Oncol. 2024;42(17suppl):TPS8605–8605.
7. Mai HQ Liu SL Chen QY Tang LQ Jin F Guo L Luo H Hu Y Liu H Liang JH Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial J Clin Oncol 2024 42 16suppl 6001 6001 10.1200/JCO.2024.42.16_suppl.6001
Mai HQ, Liu SL, Chen QY, Tang LQ, Jin F, Guo L, Luo H, Hu Y, Liu H, Liang JH. Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial. J Clin Oncol. 2024;42(16suppl):6001–6001.10.1200/JCO.2024.42.16_suppl.6001
8. Liu H Qiu B Zhao Y He W-z Feng W Zeng W Jia J Meng F Wang D Liu F A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091) J Clin Oncol 2024 42 16suppl 8008 8008 10.1200/JCO.2024.42.16_suppl.8008
Liu H, Qiu B, Zhao Y, He W-z, Feng W, Zeng W, Jia J, Meng F, Wang D, Liu F. A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091). J Clin Oncol. 2024;42(16suppl):8008–8008.10.1200/JCO.2024.42.16_suppl.8008
9. Mowery YM Ballman KV Hong AM Schuetze S Wagner AJ Monga V Heise R Attia S Choy E Burgess MA SU2C-SARC032: a randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma J Clin Oncol 2024 42 16suppl 11504 11504 10.1200/JCO.2024.42.16_suppl.11504
Mowery YM, Ballman KV, Hong AM, Schuetze S, Wagner AJ, Monga V, Heise R, Attia S, Choy E, Burgess MA, et al. SU2C-SARC032: a randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma. J Clin Oncol. 2024;42(16suppl):11504–11504.10.1200/JCO.2024.42.16_suppl.11504
10. Bradley J Sugawara S Lee K Ostoros G Demirkazik A Zemanova M Sriuranpong V Gelatti A Menezes J Zurawski B LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: final results from PACIFIC-2 ESMO Open 2024 9 3suppl 102986 10.1016/j.esmoop.2024.102986
Bradley J, Sugawara S, Lee K, Ostoros G, Demirkazik A, Zemanova M, Sriuranpong V, Gelatti A, Menezes J, Zurawski B. LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: final results from PACIFIC-2. ESMO Open. 2024;9(3suppl):102986.10.1016/j.esmoop.2024.102986
11. Chen D Gao A Zou B Huang W Shao Q Meng X Zhang P Tang X Hu X Zhang Y Guo J Zhao W Fu L Zhao C Yuan J Yu J Wang L Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer J Clin Oncol 2024 42 16suppl 8014 8014 10.1200/JCO.2024.42.16_suppl.8014
Chen D, Gao A, Zou B, Huang W, Shao Q, Meng X, Zhang P, Tang X, Hu X, Zhang Y, Guo J, Zhao W, Fu L, Zhao C, Yuan J, Yu J, Wang L. Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer. J Clin Oncol. 2024;42(16suppl):8014–8014.10.1200/JCO.2024.42.16_suppl.8014
12. Nosaki K Zenke Y Nomura S Sasaki T Niho S Yoh K Yoshioka H Hosomi Y Okamoto I Kaneda H Akamatsu H Okamoto H Sasaki K Sekino Y Horinouchi H Ohe Y JCOG2002: a randomized phase III study of thoracic radiotherapy for extensive stage small cell lung cancer J Clin Oncol 2024 42 16suppl TPS8132 8132 10.1200/JCO.2024.42.16_suppl.TPS8132
Nosaki K, Zenke Y, Nomura S, Sasaki T, Niho S, Yoh K, Yoshioka H, Hosomi Y, Okamoto I, Kaneda H, Akamatsu H, Okamoto H, Sasaki K, Sekino Y, Horinouchi H, Ohe Y. JCOG2002: a randomized phase III study of thoracic radiotherapy for extensive stage small cell lung cancer. J Clin Oncol. 2024;42(16suppl):TPS8132–8132.10.1200/JCO.2024.42.16_suppl.TPS8132
